Skyroot completes fairing separation test, preps for Vikram-1 launch
However, once the rocket reaches the vacuum of space, this bulky structure must separate flawlessly to allow the satellite payload to continue its journey to orbit. Any malfunction during this separation could jeopardize the mission.After numerous design iterations, rigorous simulations, and extensive testing, Skyroot's engineering team validated the PLF separation mechanism, confirming its readiness for flight. The company expressed immense pride in this achievement, emphasizing the dedication and tireless efforts of its team members who worked relentlessly to perfect the system.The payload fairing separation is a complex and vital operation, and its flawless execution is crucial for the success of Vikram-1. With this validation, Skyroot is one step closer to delivering reliable and cost-effective space access for India's burgeoning satellite industry.Vikram-1 is designed to carry small satellites into low Earth orbit, catering to a growing demand for affordable launch services. The rocket's development represents a significant leap forward for India's private space sector, aiming to complement government-led missions and foster a competitive commercial space ecosystem.With the PLF separation test successfully behind them, Skyroot Aerospace is now focused on final preparations for the Vikram-1 launch, anticipated later this year. Must Watch
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Economic Times
an hour ago
- Economic Times
Battlefield 6 open beta starts this week: How to join, rewards and timings revealed
The beta, which runs from 7–8 August this week, was originally only available to Battlefield Labs testers and anyone who tuned into the game's multiplayer reveal stream on 31 July Electronic Arts has announced it'll be hosting a number of beta tests for Battlefield 6 in the lead-up to launch. EA is offering a second chance for players to get into Battlefield 6's early access beta. The beta, which runs from 7–8 August this week, was originally only available to Battlefield Labs testers and anyone who tuned into the game's multiplayer reveal stream on 31 July. On Thursday, August 7, 2025, fans jumped at the chance to try it out — but massive queues formed as eager players rushed in for early access ahead of this weekend's full open beta launch. According to GamesRadar, you need to fulfill any of these criteria to be eligible:-You signed up to Battlefield Labs before July 31, then log in with the EA Account you registered watched select creators on Twitch during the July 31 reveal streams to unlock an early access code (see below). You are an EA Play Pro subscriber, then log in with the EA Account linked to your You watch creators streaming Battlefield 6 on Twitch for 30 minutes during the early access period on August 7 and 8 (see below).ALSO READ: Eli Lilly's experimental GLP-1 pill may rival Ozempic and Wegovy? Check how much weight you could lose Early Access7th — 8th AugustWeekend 19th — 10th AugustWeekend 214th — 17th AugustThe Battlefield 6 beta is taking place over the course of three stages, two of which shall be open for everyone to play no matter whether they have a code or not. Pre-Load is available now, and you can play the beta on PS5, Xbox Series X|S, and PC (Steam, Epic Games Store, EA App).North America: 1am PDT / 2am MDT / 3am CDT / 4am EDTUK/Ire: 9am BSTEurope: 10am CEST / 11am EESTAsia/Oceania: 5pm JST / 4pm AWST / 6pm AESTYour Local Time: 1:30pm, Thu 7th Aug 2025 India Standard Time ALSO READ: Firefly Aerospace ignites Wall Street as it raises $868 million in biggest space IPO. All about SpaceX rival Battlefield 6 is also running two open beta weekends later in August, but this early access beta will be the first chance most players will have to test out the game. There are two ways players can still get access to this Arts is launching its first early access beta for Battlefield 6 from August 7 to 8. Players who registered for Battlefield Labs, subscribed to EA Play Pro, or viewed the game's multiplayer reveal will automatically gain access to the beta. Everyone else will need to wait for the upcoming open beta EA has provided an alternative way for fans to join this weekend's early access. By watching 30 minutes of eligible Battlefield 6 streams on Twitch, players can earn a beta access code. Once received, the code can be redeemed on the official Battlefield 6 website to jump into the action. ALSO READ: $1,702 stimulus check in August: Last chance to apply for PDF closes soon. Check key dates, eligibility, tax implication It's on PC with Steam, the EA app, Playstation 5, Xbox X and S and the Epic Games store. What's the latest update on accessing the Battlefield 6 open beta queues and servers? Per the official X (formerly Twitter) account, you might have to wait, although they're working on increasing "server capacity" — BattlefieldComm (@BattlefieldComm) — BattlefieldComm (@BattlefieldComm) — BattlefieldComm (@BattlefieldComm) In order to get a Battlefield 6 beta early access code, you must have either taken part in Battlefield Labs before today's reveal or watch Twitch streamers to get a code through a Twitch Drop. Therefore, your options are:All participants in Battlefield Labs from before today (31st July) get early access to the beta. Watch currently live Twitch streamers to get an early access code in a Twitch Drop ALSO READ: Powerball ticket hits $1 million prize in US: Check next drawing date, winning numbers and where to buy lottery tickets Weekend 1: August 9–10Complete the following challenges to unlock:Lights Out Player Card – Reach Level 10Rising Star Character Skin – Reach Level 15Night Terror Weapon Charm – Reach Level 20Striking Distance Weapon Package – Score 50 close-quarters kills (within 10m, using Assault class)Own the Night Weapon Sticker – Revive 100 teammates (Support class)After Dark Weapon Sticker – Repair 3,000 vehicle health (Engineer class)Seeker Character Skin – Spot 300 enemies (Recon class)Weekend 2: August 14–17Take on these challenges to earn:War Machine Vehicle Skin – Capture 42 flags in Conquest, Domination, or King of the HillBat Company Dog Tag – Get 200 kills or assistsDominion Weapon Package – Capture 10 sectors in Breakthrough or Rush
Economic Times
an hour ago
- Economic Times
Eli Lilly's experimental GLP-1 pill may rival Ozempic and Wegovy? Check how much weight you could lose
Eli Lilly's experimental weight loss pill, orforglipron, demonstrated an average weight loss of 12% in a late-stage trial, falling short of Wall Street's expectations. Despite the positive results, shares of Eli Lilly fell, while rival Novo Nordisk's shares rose. The company plans to seek regulatory approval for the pill by the end of 2025. Tired of too many ads? Remove Ads Tired of too many ads? Remove Ads Eli Lily on daily GLP-1 pills Eli Lilly's weight loss pill doesn't appear to work as well as Wall Street had hoped. The drugmaker said Thursday the highest dose of its daily obesity pill helped patients lose almost 12% of their body weight, or roughly 27 pounds, at 72 weeks in a late-stage trial. The result falls on the lower end of Wall Street's of the company fell around 13% on Thursday, according to CNBC. Meanwhile, shares of rival Novo Nordisk, which is also working to bring an obesity pill to the market, jumped more than 7% on Lilly, which makes the injectable drugs Zepbound to treat obesity and Mounjaro and Trulicity to treat diabetes, is among several companies chasing an effective pill form of GLP-1s. The only such pill available so far comes with strict diet restrictions and is approved to treat says that no food or water restrictions are needed with the experimental oral medication, orforglipron, and it can be taken any time of Lilly announced that its new orforglipron pill led to an average weight loss of up to 27.3 pounds, based on results from the first of two Phase 3 trials involving over 3,100 overweight or obese adults."With orforglipron, we're working to transform obesity care by introducing a potential once-daily oral therapy that could support early intervention and long-term disease management, while offering a convenient alternative to injectable treatments," Kenneth Custer, an executive vice president and president of Lilly Cardiometabolic Health, said in a statement. "With these positive data in hand, we are now planning to submit orforglipron for regulatory review by year-end and are prepared for a global launch to address this urgent public health need."Investors had high hopes that Lilly's pill, orforglipron, would match the effectiveness of Novo Nordisk's blockbuster weight-loss injection, Wegovy . In key trials, Wegovy helped users lose around 14% to 15% of their body weight — slightly below the weight loss seen with Lilly's competing shot, Zepbound.'There was hope that this would be a wonder drug,' BMO analyst Evan Seigerman said of Lilly's pill. 'What this shows to me is that it's still a good drug, but it's bound by the limitations of being a GLP-1.'Eli Lilly said that all adults participating in its Phase 3 trials experienced weight loss while taking orforglipron. Participants on the highest dose—36 mg—lost an average of 27 pounds over 72 weeks, equating to about 12% of their body weight. While this result is significant, it falls slightly short of the weight loss typically seen with some injectable treatments with the drugmaker noticing that about 10% of participants on the highest dose chose to discontinue the weight loss, trial participants saw improvements in cardiovascular markers, including reductions in systolic blood pressure, non-HDL cholesterol, and triglycerides. Negative side effects were similar in frequency and nature to those observed with injectable GLP-1 medications. The most commonly reported side effects were mild to moderate gastrointestinal issues such as nausea, constipation, indigestion, diarrhea, and Lilly is also evaluating orforglipron's effectiveness in adults with Type 2 diabetes. In April, the company shared that the pill may help lower hemoglobin A1C levels—a key indicator of average blood sugar over two to three months—while also supporting weight Lilly aims to seek global regulatory approval for its daily oral orforglipron pill by the end of 2025, positioning itself alongside rival Novo Nordisk, which is pursuing approval for an oral form of its Wegovy (semaglutide) treatment. However, federal health regulators are expected to require more comprehensive data on the drug's safety, tolerability, and effectiveness before moving forward with any potential approval.
Mint
3 hours ago
- Mint
Eli Lilly shares tumble over 10% after disappointing weight-loss pill data
Eli Lilly & Co. tumbled as disappointing data on its new weight-loss pill overshadowed strong growth from the company's current obesity medicine, which helped drive it to raise its yearly profit and sales outlook. Lilly's results from an obesity pill study, a drug key to unlocking billions of dollars of growth, didn't perform as well as Wall Street expected. It resulted in lower weight loss and higher rates of nausea and vomiting than anticipated, side effects associated with so-called GLP-1 drugs. The data was a boon for rival Novo Nordisk A/S. 'There was hope that this would be a wonder drug,' BMO analyst Evan Seigerman said of Lilly's pill. 'What this shows to me is that it's still a good drug, but it's bound by the limitations of being a GLP-1.' Lilly fell more than 10% when markets opened in New York on Thursday. Novo rose as much as 14.3% in Copenhagen, the most in almost four months. Drugmakers are in a hotly contested race to dominate the market for obesity medications. Lilly had moved into pole position against Novo thanks to Zepbound, its powerful injectable drug, but Lilly's sky-high valuation is tied in part to eventually turning its weight-loss pill into a blockbuster. Investors say pills are a vital part of reaching more patients in the market that's expected to grow to $95 billion by 2030. But the science has proved to be a challenge. Pfizer Inc. and AstraZeneca Plc are among a handful of companies that have faced setbacks as they race to develop potent pills of their own. In Lilly's pill study, patients on the highest dose shed roughly 11% of their body weight, or 25 pounds, the company said. In late-stage trials, patients on Novo's injectable Wegovy lost about 15% of their weight over a 68-week period. The most common side effects were nausea, vomiting and diarrhea, which occurred at rates similar to existing GLP-1 drugs, Lilly said in a statement detailing the results. Notably, the medication didn't cause liver issues, a concern with other weight-loss pills in development. About 10% of patients dropped out of the study due to side effects. Lilly's data raise doubts over whether the pill, called orforglipron, can meet Wall Street's estimates of $12 billion in annual sales by 2030, Bloomberg Intelligence analysts John Murphy and Christos Nikoletopoulos wrote. The company defended the results, and said that small differences in weight loss in a clinical trial are of little importance to doctors and their patients. 'I know Wall Street has kind of focused on the exact numbers here and making cross-trial comparisons, but I don't think that carries over to to the real world at all,' Lilly Chief Scientific Medical Officer Daniel Skovronsky said on a conference call. The company plans to submit the findings from the 18-month study involving more than 3,100 adults to regulatory agencies for approval by the end of the year. Detailed results will be presented at a medical conference in September. If approved, Lilly's once-daily pill would likely hit pharmacy shelves next year. Orforglipron is easier to manufacture than its current injectable Zepbound and is expected to be a cheaper option for patients. Novo has filed an oral version of its weight-loss blockbuster Wegovy for US approval, but it's more complicated to produce than Lilly's and will likely have more dosing restrictions, such as when patients can eat and drink. For investors, it has been a further example of Novo slipping behind after its next-generation obesity drug, CagriSema, also fell short of expectations in clinical trials. But Lilly's result offered Novo a welcome narrative shift on the same day that Maziar Mike Doustdar takes over as CEO from Lars Fruergaard Jorgensen. Novo executives said their pill had the potential to be the best in its class on a call Thursday afternoon with analysts after Lilly's pill data was released. 'The numbers speak for themselves,' Chief Scientific Officer Martin Holst Lange said. On Thursday, Lilly also increased its sales projections for the year and now expects revenue between $60 billion and $62 billion, up from a range of $58 billion to $61 billion. The company said in a statement it expects 2025 profit to reach $21.75 to $23 a share, up from $20.78 to $22.28. Lilly's second-quarter sales were $15.6 billion, beating analysts' average estimates of $14.7 billion. Zepbound surpassed expectations, while the diabetes medicine Mounjaro beat the Street's view. Adjusted profits were $6.29 per share, which outpaced analysts' $5.57 per share expectation. The company expects CVS Health Corp.'s decision to drop Zepbound from its preferred list of medications for pharmacy patients to slow third-quarter growth. CVS earlier this year negotiated a deal with Novo to make Wegovy cheaper for health plans. Lilly executives initially shrugged off concerns over the move, but Chief Financial Officer Lucas Montarce said Thursday it took a bite out of Zepbound prescriptions in July. Adding to pressure, the entire pharmaceutical industry faces the threat of sector-specific tariffs and policies that would restrict what they can charge for medicines in the US. President Donald Trump said in a television interview on Tuesday pharma tariffs would be announced 'within the next week or so.' Last week, Trump also sent letters to 17 of the largest drugmakers, demanding they slash the price of medicines for US customers. Chief Executive Officer Dave Ricks was one of the executives to receive a personal letter from the president. The CEO said the company would work with the administration but warned that Trump's so-called most-favored nation policy could 'import foreign price controls' into a complex US system. 'We risk embracing the worst of two worlds: the low productivity and output of Europe's biopharma sector and the high out-of-pocket costs and distorted prices of the US insurance market,' Ricks said on a conference call with analysts.
